<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Troxacitabine has significant single-agent activity </plain></SENT>
<SENT sid="1" pm="."><plain>This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C), <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, or topotecan </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Patients with refractory <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), advanced <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BP) were initially randomly assigned to receive troxacitabine 5.0 mg/m(2) by intravenous (IV) infusion over 30 minutes on days 1 to 5 with ara-C 1.0 g/m(2)/d IV [DOSAGE ERROR CORRECTED] over 2 hours on days 1 to 5, <z:chebi fb="0" ids="42068">idarubicin</z:chebi> 12 mg/m(2) by 5 minute IV infusion on days 1 to 3, or topotecan 1.0 mg/m(2) as an continuous IV infusion on days 1 to 5 </plain></SENT>
<SENT sid="3" pm="."><plain>Doses were then adjusted to define DLT for each combination </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Eighty-seven patients (68 AML, eight <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 11 <z:mp ids='MP_0005481'>CML</z:mp>-BP) were treated </plain></SENT>
<SENT sid="5" pm="."><plain>DLTs were hepatic transaminitis, <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, and <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand foot syndrome</z:e> (HFS) on the troxacitabine plus ara-C combination </plain></SENT>
<SENT sid="6" pm="."><plain>The recommended phase II doses were 6 mg/m(2) once a day for 5 days and 1.0g/m(2) once a day for 5 days, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>DLTs were <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, and mucositis on the troxacitabine plus topotecan combination </plain></SENT>
<SENT sid="8" pm="."><plain>The recommended phase II doses were 4 mg/m(2) once a day for 5 days and 0.75 mg/m(2) once a day for 5 days, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>DLTs were HFS, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, and mucositis on the troxacitabine plus <z:chebi fb="0" ids="42068">idarubicin</z:chebi> combination </plain></SENT>
<SENT sid="10" pm="."><plain>The recommended phase II doses were 4 mg/m(2) once a day for 5 days and 9 mg/m(2) once a day for 3 days, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Among 74 evaluable patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 10 (13%) achieved complete remission and four (5%) had hematologic improvement </plain></SENT>
<SENT sid="12" pm="."><plain>Two of 11 (18%) evaluable patients with <z:mp ids='MP_0005481'>CML</z:mp>-BP returned to <z:hpo ids='HP_0011010'>chronic</z:hpo> phase </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Troxacitabine-based combinations had significant antileukemic activity </plain></SENT>
</text></document>